Clinical trial DESTINY-Breast15
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (BC) (DESTINY-Breast15)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Daiichi Sankyo |
| EudraCT Identifier | 2023-505616-38-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05950945 |
| Inclusion criteria | Unresectable and/or Metastatic HER2-low orHER2 Immunohistochemistry (IHC) 0 Breast Cancer |
| Last update |